GlassScriptPhysician profile
Sandra F Globus
NPI 1912110784
$5,847.40
in general payments reported to CMS, 2019-2025
39 companies · $657 in 2025
The $657 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,632 · 2022: $1,438 · 2023: $1,248 · 2024: $874 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $963.50 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $578.74 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $564.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $482.11 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.35 | 2021-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $308.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $255.23 | 2021-2023 | Fasenra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $235.12 | 2021-2025 | |
| Almatica Pharma LLC | $182.01 | 2023 | Loreev Xr, Gralise |
| Boston Scientific Corporation | $181.93 | 2022-2024 | Wavewriter Alpha Prime 16, Watchman Flx |
| Amgen INC. | $166.11 | 2021-2025 | Otezla, Repatha, Otezla |
| Esperion Therapeutics, INC. | $161.21 | 2021-2022 | |
| Astellas Pharma US INC | $141.98 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $122.24 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.97 | 2022-2025 | Caplyta |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Globus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.